Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis.
Patricia Pozo-RosichKaren H SamaanTodd J SchwedtRobert A NicholsonMallikarjuna RettigantiEric M PearlmanPublished in: Advances in therapy (2021)
ClinicalTrials.gov identifier: EVOLVE-1 (NCT02614183); EVOLVE-2 (NCT02614196); REGAIN (NCT02614261).